MedTrace Logo

A Phase I Study of CDX-622

NCT06650761 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2026-05-04

No results posted yet for this study

Summary

This is a study to determine the safety of CDX-622 in healthy participants.

Conditions

  • Healthy Participants

Interventions

DRUG

CDX-622

Up to 4 infusions of one of seven dosages of CDX-622 or up to 1 dose by subcutaneous injection of one of three dosages of CDX-622

DRUG

Normal Saline

Up to 4 infusions or 6 SC injections of normal saline

Sponsors & Collaborators

  • Celldex Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2026-04-24
Completion
2026-04-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06650761 on ClinicalTrials.gov